Literature DB >> 15662121

Cell cycle regulation and hepatocarcinogenesis.

Linda E Greenbaum1.   

Abstract

Hepatocellular carcinoma (HCC) develops on a background of chronic hepatitis or cirrhosis. The slow progression of this disease has facilitated the identification of discrete pathologic stages. Increased rates of hepatocyte proliferation in preneoplastic nodules is an early event in the progression of HCC. Increased cell turnover results in the selection of monoclonal hepatocyte populations that subsequently undergo genomic alterations that lead to the development of HCC. The heterogeneous nature of genomic alterations identified in tumors from patients with HCC has impeded the identification of regulatory pathways whose disruption are critical for tumor initiation. However, several regulatory networks important for liver cell proliferation have been characterized using the partial hepatectomy model, an in vivo model of liver cell cycle progression, and are likely relevant to the pathogenesis of hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2004        PMID: 15662121     DOI: 10.4161/cbt.3.12.1392

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  25 in total

1.  Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Authors:  Tae-Min Kim; Seon-Hee Yim; Seung-Hun Shin; Hai-Dong Xu; Yu-Chae Jung; Cheol-Keun Park; Jong-Young Choi; Won-Sang Park; Mi-Seon Kwon; Heike Fiegler; Nigel P Carter; Mun-Gan Rhyu; Yeun-Jun Chung
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

2.  MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.

Authors:  C Wan; S Hou; R Ni; L Lv; Z Ding; X Huang; Q Hang; S He; Y Wang; C Cheng; X X Gu; G Xu; A Shen
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

3.  Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells.

Authors:  Chengzhi Xie; Guoxing Liu; Jiefeng Liu; Zhao Huang; Fusheng Wang; Xiaohua Lei; Xiaolong Wu; Shengfu Huang; Dewu Zhong; Xundi Xu
Journal:  Oncol Lett       Date:  2012-06-11       Impact factor: 2.967

4.  Machine-learning algorithms based on personalized pathways for a novel predictive model for the diagnosis of hepatocellular carcinoma.

Authors:  Binglin Cheng; Peitao Zhou; Yuhan Chen
Journal:  BMC Bioinformatics       Date:  2022-06-23       Impact factor: 3.307

5.  Spatiotemporal expression of HMGB2 regulates cell proliferation and hepatocyte size during liver regeneration.

Authors:  Koichi Yano; Narantsog Choijookhuu; Makoto Ikenoue; Tomohiro Fukaya; Katsuaki Sato; Deokcheol Lee; Noboru Taniguchi; Etsuo Chosa; Atsushi Nanashima; Yoshitaka Hishikawa
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

6.  Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients.

Authors:  Jens U Marquardt; Kerstin Fischer; Katharina Baus; Anubha Kashyap; Shengyun Ma; Markus Krupp; Matthias Linke; Andreas Teufel; Ulrich Zechner; Dennis Strand; Snorri S Thorgeirsson; Peter R Galle; Susanne Strand
Journal:  Hepatology       Date:  2013-07-30       Impact factor: 17.425

Review 7.  Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda; Toshifumi Wakai; Masayuki Kubota; Masaaki Takamura; Satoshi Yamagiwa; Yutaka Aoyagi; Mami Osawa; Shun Fujimaki; Ayumi Sanpei; Takuya Genda; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2013-05-03       Impact factor: 2.309

8.  Lack of increases in methylation at three CpG-rich genomic loci in non-mitotic adult tissues during aging.

Authors:  Michelle W Chu; Kimberly D Siegmund; Carrie L Eckstam; Jung Yeon Kim; Allen S Yang; Gary C Kanel; Simon Tavaré; Darryl Shibata
Journal:  BMC Med Genet       Date:  2007-07-31       Impact factor: 2.103

9.  Numb downregulation suppresses cell growth and is associated with a poor prognosis of human hepatocellular carcinoma.

Authors:  Chengzhi Xie; Zhenhui Lu; Guoxing Liu; Yu Fang; Jiefeng Liu; Zhao Huang; Fusheng Wang; Xiaolong Wu; Xiaohua Lei; Xiaocheng Li; Yueming Zhang; Zecheng Hu; Ke Qian; Jixiong Hu; Shengfu Huang; Dewu Zhong; Xundi Xu
Journal:  Int J Mol Med       Date:  2015-07-09       Impact factor: 4.101

10.  Hydroxysteroid sulfotransferase SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and in vivo.

Authors:  Xiaoming Yang; Yali Xu; Fenghua Guo; Yanxia Ning; Xiuling Zhi; Lianhua Yin; Xiaobo Li
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.